September 17 - 20, 2019
DoubleTree by Hilton Montreal
Montreal, QC, Canada
Abstract submission deadline: Thursday, June 27
Advance registration deadline: Tuesday, August 6
Tuesday, Sept. 17, 2019
Wednesday, Sept. 18, 2019
Thursday, Sept. 19, 2019
Friday, Sept. 20, 2019
Tuesday, Sept. 17
Opening Plenary Session5-6:30 p.m.
Pediatric neuro-oncology: What's next?Stefan M. Pfister, Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ) and German Cancer Research Center, Heidelberg, Germany
Three-hit model of Wilms tumor formation reveals immunogenic transcriptional subtypes*Kenneth Chen, University of Texas Southwestern, Dallas, Texas
Generation of the first genetically defined tumorigenic model of Ewing sarcoma expressing EWS-FLI1*Nilay Shah, Nationwide Children's Hospital, Columbus, Ohio
Opening Reception6:30-8 p.m.
Top of pageWednesday, Sept. 18
Continental Breakfast with Networking Roundtables7-8 a.m.
Plenary Session 1: Cancer Predisposition and SurveillanceSession Chair: David Malkin, The Hospital for Sick Children, Toronto, ON, Canada8-10:15 a.m.
Sex ratio disparities and the risk of childhood cancer: Evaluating the mediating effect of birth defects among 15,000 childhood cancer cases*Erin Marcotte, University of Minnesota, Minneapolis, Minnesota
Novel strategies for early cancer detection and prevention: The Li-Fraumeni Syndrome storyDavid Malkin
Medulloblastoma predisposition according to molecular subgroup: The usual suspects and beyondPaul A. Northcott, St. Jude Children’s Research Hospital, Memphis, Tennessee
New approaches to study cancer predisposition syndromesChristian P. Kratz, Hannover Medical School, Hannover, Germany
Circulating tumor DNA as a tool for prognostication, translational discovery, and early cancer detection Brian Crompton, Boston Children’s Hospital, Boston, Massachusetts
New strategies for multidimensional molecular characterization and follow-up of high-risk pediatric cancersGudrun Schleiermacher, Institut Curie, Paris, France
Plenary Session 2: Immunotherapy I – Cellular Therapies Session Chair: Crystal L. Mackall, Stanford University School of Medicine, Stanford, California10:30 a.m.-12:30 p.m.
Next-generation CAR T cells to overcome resistanceCrystal L. Mackall
Plenary Session 3: Immunotherapy II – Immune Checkpoint Inhibition and Tumor MicroenvironmentSession Chair: Paul Sondel, University of Wisconsin School of Medicine, Madison, Wisconsin2:30-4:30 p.m.
Activating innate and adaptive immunity to improve outcome for "COLD" tumorsPaul Sondel
Overcoming immune evasion in pediatric brain tumorsRobert J. Wechsler-Reya, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California
Special Session 1: Lightning LecturesSession Chair: David Malkin, The Hospital for Sick Children, Toronto, ON, Canada4:30-4:45 p.m.Lightning Lectures highlight the top research that will be presented as posters. Select abstracts from Poster Session A will be featured in this session. Presenters will have one minute to present one slide to highlight their most exciting finding. We invite you to discuss these in greater depth during the poster session. Prevalence and spectrum of germline mutations in children with high-risk cancer*Noemi Fuentes-Bolanos, Kid's Cancer Center, Sydney, NSW, Australia
A comprehensive and integrative omic analysis of multiply relapsed refractory pediatric pre-B cell acute lymphoblastic leukemia predicts response to CD19 CAR T-cell therapy*Katherine Masih, National Institutes of Health, Bethesda, Maryland
Glypican-2 targeted CAR T-cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity*Sabine Heitzeneder, Stanford Cancer Institute, Stanford, California
Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and Bispecific T Cell Engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy*Adam Cheuk, National Cancer Institute, Bethesda, Maryland
Targeted sequencing in 388 patients with high-risk or recurrent/refractory pediatric extracranial solid malignancies: An interim report from the GAIN Consortium/iCat2 Study*Laura Corson, Dana-Farber Cancer Institute, Boston, Massachusetts
BMI1 constitutes a novel therapeutic vulnerability in fusion-positive rhabdomyosarcoma*Robert Schnepp, Emory University School of Medicine, Atlanta, Georgia
Charting the synthetic lethality landscape in pediatric cancer to advance whole-exome precision-based treatments*Fiorella Schischlik, National Cancer Institute, Bethesda, Maryland
Defining the transcriptional regulation of pediatric AML as a new strategy to find potential druggable vulnerabilities*Joanna Yi, Baylor College of Medicine, Houston, Texas
EphB2 a potential therapeutic target for pediatric medulloblastoma*Yuchen Li, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
Zero childhood cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer*Vanessa Tyrrell, Children's Cancer Institute, Sydney, NSW, Australia
Validation of potential therapies for treatment of fatal pediatric brain tumors DIPG and AT/RT using a novel rapid intracranial model in zebrafish*Harpreet Kaur, Johns Hopkins University, Baltimore, Maryland
Overcoming challenges in health care with machine learning: Innovation from retinoblastoma*Isabella Janusonis, The Hospital for Sick Children, Toronto, ON, CanadaPoster Session A / Reception4:45-7:15 p.m.
Top of pageThursday, Sept. 19
Continental Breakfast with Networking Roundtables7-8 a.m.
Plenary Session 4: Molecularly Targeted TherapiesSession Chair: Gilles Vassal, Institut Gustave Roussy, Villejuif, France8-10 a.m.
Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impactKatherine A. Janeway, Dana-Farber Cancer Institute, Boston, Massachusetts
Tissue-agnostic development of TRK inhibitors for pediatric cancerTheodore Laetsch, University of Texas Southwestern Medical Center, Dallas, Texas
Special Session 2: Lightning LecturesSession Chair: David Malkin, The Hospital for Sick Children, Toronto, ON, Canada12:30-12:50 p.m.Lightning Lectures highlight the
top research that will be presented as posters. Select abstracts from
Poster Session B will be featured in this session. Presenters will have
one minute to present one slide to highlight their most exciting
finding. We invite you to discuss these in greater depth during the
A C19MC-LIN28A-MYCN oncogenic circuit driven by hijacked super-enhancers is a distinct therapeutic vulnerability in ETMRs—a lethal brain tumor*Iqra Mumal, The Hospital for Sick Children, Toronto, ON, Canada
MECOM dysregulation is associated with poor outcome in pediatric therapy-related myeloid neoplasms*Tamara Lamprecht, St. Jude Children's Research Hospital, Memphis, TennesseeGenomic classification and prognosis in rhabdomyosarcoma: A report from the Children’s Oncology Group, the Institute of Cancer Research, and the National Cancer Institute*Javed Khan, National Cancer Institute, Bethesda, Maryland
Beyond synthetic lethality: Multiple mechanisms can explain genetic interactions within childhood cancer*Josephine Daub, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Ewing sarcoma: A case study of clonal aneuploidy and DNA damage repair in pediatric cancer*Xiaofeng Su, Koch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts
A CRISPR/Cas9 domain screen identifies a small motif in the PAX3-FOXO1 transactivation domain relevant for tumor maintenance in alveolar rhabdomyosarcoma*Marco Wachtel, University Children's Hospital Zurich, Zurich, Switzerland
CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb Repressive complex 2 via a H3K27M-like mechanism*Andrea Piunti, Northwestern University, Chicago, Illinois
EWS-FLI1 orchestrates Ewing sarcoma plasticity through a post-translational modification cascade regulating FOXM1 stability*Heinrich Kovar, St. Anna Children's Cancer Research Institute, Vienna, Austria
Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma*Myron Ignatius, Greehey Children's Cancer Research Institute, University of Texas Health Sciences Center, San Antonio, Texas
Modeling a pathogenic SAMD9 mutation in human induced pluripotent stem cells*Jason Schwartz, St. Jude Children's Research Hospital, Memphis, Tennessee
Mutant RAS represses CASZ1, a novel regulator of MYOD and MYOG, to inhibit embryonal rhabdomyosarcoma differentiation*Zhihui Liu, National Cancer Institute, Bethesda, Maryland
Overexpression of TLX3 or HOXA9 in association mutant IL7Rα is sufficient to generate T-ALL in vivo*Gisele Rodrigues, National Cancer Institute, Frederick, Maryland
Validation of a model of pedriatric leukemia based on pluripotent stem cells using mass cytometry*Joan Domingo Reines, Pfizer/University of Granada/Junta de Andalucía, Granada, Spain
Characterizing vascular invasion in hepatoblastoma*Sarah Woodfield, Baylor College of Medicine, Houston, Texas
Dissecting the heterogeneity of metastatic neuroblastoma cells by single-cell RNA-seq*Alice Shan, University of Toronto, Toronto, ON, Canada
Investigating the role of tumor:bone microenvironment crosstalk in Ewing sarcoma progression*Kelsey Temprine, University of Michigan Medical School, Ann Arbor, Michigan
Epigenomics and single-cell sequencing define a developmental hierarchy in Langerhans cell histiocytosis*Caroline Hutter, St. Anna Children's Cancer Research Institute, Vienna, Austria
Spatial and temporal conditions for Smarcb1 deletion determines mouse AT/RT (atypical teratoid/rhabdoid tumor) subtype*Zhi-Yan Han, institut Curie, Paris, France
Three distinct subgroups of Wilms' tumors with novel molecular features and important clinical implications are defined by genome-wide DNA methylation profiles*Jack Brzezinski, Hospital for Sick Children, Toronto, ON, Canada
Poster Session B / Lunch12:50-3:15 p.m.
Top of page
Plenary Session 6: Pathways of Oncogenesis II: Basic BiologySession Chair: E. Alejandro Sweet-Cordero, University of California San Francisco, San Francisco, California3:15-5:15 p.m.
Blocking purine synthesis in cancer promotes response to immunotherapyAyelet Erez, Weizmann Institute of Science, Rehovot, Israel
Tumor cells hijack diverse cellular processes to maintain redox balance Poul H.B. Sorensen, BC Cancer Research Centre, Vancouver, BC, Canada
Lessons from a rare childhood cancer syndrome on replication repair deficiency and hypermutation Uri Tabori, The Hospital for Sick Children, Toronto, ON, Canada
Lactate dehydrogenase A is a pharmacologically tractable EWS-FLI1 transcriptional target that regulates the glycolytic dependence of Ewing sarcoma*Christine Heske, National Cancer Institute, Bethesda, Maryland
STAG2 mutations alter topologic organization of the genome and cis-mediated interactions*Didier Surdez, Institut Curie, Paris, France
Special Session 3: Hot Topics in Pediatric Cancer Research from Highly Rated Abstracts Session Chair: Adam Shlien, The Hospital for Sick Children, Toronto, ON, Canada5:15-6:30 p.m.
Disruption of IL6-mediated paracrine signaling to prevent pulmonary metastasis*John Hinckley, The Ohio State University, Nationwide Children's Hospital, Columbus, Ohio
EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma*Adam Durbin, Dana-Farber Cancer Institute, Boston, Massachusetts
IL6-mediated self-seeding functions to prevent osteosarcoma metastasis*Amy Gross, Nationwide Children's Hospital, Columbus, Ohio
Surgical excision of the primary tumor in osteosarcoma model results in enhanced metastatic growth by modulating the lung immune microenvironment*Michelle Kallis, The Elmezzi Graduate School of Molecular Medicine, Northwell Health, Karches Center for Oncology, The Feinstein Institute for Medical Research and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York
Ewing sarcoma cells exploit the IL1RAP-CTH axis to drive oxidative stress adaptation and lung metastasis*Haifeng Zhang, University of British Columbia, Vancouver, BC, Canada
Friday, Sept. 20
Continental Breakfast with Networking Roundtables7-8 a.m.
Plenary Session 7: Survivorship ResearchSession Chair: Gregory T. Armstrong, St. Jude Children’s Research Hospital, Memphis, Tennessee8-9:45 a.m.
The lifetime impact of cancer and cancer therapyGregory T. Armstrong
Optimizing cancer survivorship outcomes with intervention, dissemination, and implementation researchTara O. Henderson, University of Chicago, Chicago, Illinois
The need for evidence-based survivorship careLeontien C.M. Kremer, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands
Acting at a distance: Medulloblastoma-secreted ligands disrupt normal neural stem cell function*Alexander Gont, Hospital for Sick Children, Toronto, ON, Canada
Plenary Session 8: Tumor HeterogeneitySession Chair: Sam Behjati, Wellcome Sanger Institute, Cambridge, United Kingdom10:15 a.m.-12:45 p.m.
Comprehensive transcriptomic characterization of 1,400 sarcomas for diagnosis and immune contexture*Julien Vibert, Institut Curie, Paris, France
Immunogenomic landscape of pediatric solid malignancies*Jun Wei, National Cancer Institute, Bethesda, Maryland
Closing Remarks12:45-1 p.m.
*Short talk from proffered abstractTop of page